Synergy between PPARgamma ligands and platinum-based drugs in cancer.


PPARgamma is a member of the nuclear receptor family for which agonist ligands have antigrowth effects. However, clinical studies using PPARgamma ligands as a monotherapy failed to show a beneficial effect. Here we have studied the effects of PPARgamma activation with chemotherapeutic agents in current use for specific cancers. We observed a striking… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.